Out of the Lab: Operationalizing Cell and Gene Therapy

Nicholas (Nico) Crudele
  • 0.0 (0)
  • Medicine

In Cell & Gene Therapy, opportunity created by openly discussing operational reality far outweighs the micro-risk of looking unpolished. By building a safe, unscripted space where experts can talk naturally about real work, we stop pretending everything is fine and start building the solutions needed to actually fix the system. Explore our Solution: https://www.methodmade.ca/?utm_source=podcast&utm_medium=show_notes&utm_campaign=out_of_the_lab

  1. 1h ago

    Restoring Patient Agency: Breaking the 80% Access Barrier in Cell Therapy | Michelle Hill

    In this episode of Out of the Lab, host Nico Crudele sits down with Michelle Hill, a 30-year biotech veteran, Kite Gilead alum and founder of Avenue to Care, to examine why revolutionary cell therapies like CAR T are failing to reach over 80% of eligible patients. Michelle breaks down the severe non-clinical, operational, and socioeconomic barriers keeping advanced treatments locked behind elite academic medical centers. From community physician referral gaps and geographic attrition to building data-neutral care orchestration platforms, this conversation explores how the industry can bridge the gap between treatment availability and true patient access. Key Takeaways: Why CAR T adoption has plateaued at 20% and how current access disproportionately favors patients with health literacy and financial means. How general oncologists' lack of familiarity with cell therapy risks and successes creates early patient drop-outs. The role of non-clinical care orchestration in restoring patient agency without crossing pharma compliance boundaries. Navigating post-treatment survivorship, long-term follow-up registry demands (CIBMTR), and the impact of REMS updates on patient travel requirements. Timestamps & Key Topics: 00:00:00 – Introduction & Method Made Sponsor 00:01:16 – The 80% Access Deficit & Infrastructure Gaps 00:03:32 – The 10-Mile Rule & Geographic Attrition 00:06:26 – Early Diagnoses & The Loss of Patient Agency 00:11:32 – Rare Disease, Autoimmune, and the CAR T Horizon 00:14:07 – General Oncologist Referral Hesitancy & Perceived Failures 00:17:03 – Socioeconomic Privilege in Clinical Access 00:22:17 – Introducing Avenue to Care: Public Benefit Care Orchestration 00:26:34 – Post-Treatment Care, Survivorship, & Long-Term Data Tracking 00:31:07 – Global Access Challenges & Health Literacy 00:35:12 – Rebuilding Healthcare Around the Patient

  2. Sep 29

    The 2 AM Audit Reality: Ex-FDA Regulators on CDMO Oversight, Night Shift Sins, and Data Integrity

    Why do processes that look clean on paper collapse during an FDA inspection? In this episode of Out of the Lab, host Nico Crudele sits down with ex-FDA auditors DeVaughn Edwards (GMP specialist) and Elvia Cervantes (GCP specialist) to break down the most common and preventable compliance disasters in cell and gene therapy. From night-shift compliance breakdowns and paper-only CDMO audits to data manipulation and informal quality decisions, DeVaughn and Elvia share unvarnished insights from their time inside the agency and in the field. Key Takeaways: You Can't Outsource Liability: Why delegating manufacturing to a CDMO or clinical monitoring to a CRO does not clear a sponsor's regulatory responsibility. The "Boots on the Ground" Mandate: Why paper questionnaires fail vendor qualification and how unmonitored night shifts breed compliance failures. Building Code vs. Blueprint: The cost of bringing Quality teams in midstream rather than from project inception. Data Integrity Realities: What actual record destruction and email-based decision-making signal to FDA investigators. Modern Audit Readiness: How remote regulatory assessments (RRAs), 1-day audits, and AI tools like ELSA are changing FDA oversight. Timestamps / Show Notes: 00:01:16 – The cost of involving Quality teams too late in development. 00:05:29 – Qualifying CDMOs: Why "boots on the ground" beat paper questionnaires. 00:09:08 – The 2 AM reality check: Night shift compliance breakdowns. 00:14:00 – Modern audit readiness, 1-day inspections, and FDA’s ELSA system. 00:24:43 – Data integrity red flags: Document destruction and pressure-driven cover-ups. 00:41:33 – Operational silos: When administrative assistants make escalation decisions. 00:47:32 – What an effective CAPA actually looks like. 01:05:15 – Inspecting emails and server migrations as regulatory liabilities.

  3. Sep 22

    The $1M CDMO Selection Trap & Rethinking CMC Roadmaps with Shri Joshi

    Why does selecting the cheapest CDMO quote often lead to millions of dollars in unexpected costs down the road? In this episode of Out of the Lab, host Nico sits down with industry veteran Shri Joshi, who has navigated cell and gene therapy operations across consulting, CDMO, and sponsor sides to break down the core ingredients of a successful drug development lifecycle. We explore why CDMO selection must be treated as a development and risk-management decision rather than a simple procurement task. Shri breaks down why early investments in analytical methods create crucial operational flexibility, why the adage "the process is the product" can actually harm development, and how early-stage founders can build a true "comparability mindset" to de-risk clinical progression. Key Topics Covered: 00:01:34 – The 3 core ingredients of cell & gene therapy development 00:04:20 – Why CDMO selection is a risk management decision, not procurement 00:07:28 – Case Study: Transparency vs. unrealistic timeline promises 00:18:38 – The real cost of cheap contracts: How a $1M discount cost $5M later 00:21:41 – CMC 101: Chemistry, Manufacturing, & Controls explained 00:24:37 – Why "the process is the product" dogma creates operational bottlenecks 00:27:53 – Developing analytical methods early to enable comparability 00:32:04 – Utilizing Quality Target Product Profiles (QTPP) & Process Flow Diagrams This episode is brought to you by Method Made. Accelerate your tech transfer by up to six months using video SOPs to capture technical nuance. Download the free Tech Transfer Failure Modes and Effects Analysis at methodmade.ca by clicking Download FMEA.

  4. Sep 15

    Bunny Suits, Ice Buckets, and Slashing COGS: Bridging R&D and GMP Realities with Jerry (CellBri)

    Why do brilliant R&D processes stall or fail when transferred into a GMP cleanroom? In this episode of Out of the Lab, host Nicholas Crudele sits down with Jerry from CellBri to unpack the unspoken assumptions, technical miscommunications, and equipment hurdles that delay cell therapy manufacturing. From the reality of using ice buckets instead of precise 4°C incubation to reducing batch COGS from $150,000 down to under $20,000 using flexible automation, Jerry breaks down how effective communication through documentation and smart software UX de-risk cell therapy scale-up. Key Topics Covered: The R&D vs. Cleanroom Disconnect: Why gowning, double-gloving, and workflow timing ruin unexamined bench protocols during tech transfer. The "Oral Tradition" Trap: How minor miscommunications (0°C vs. 4°C) can cause month-long troubleshooting investigations. Slashing COGS with Flexible Automation: How modern automated systems dramatically cut labor costs and production days. UX in the Cleanroom: Replacing ambiguous error codes with on-screen video guidance to prevent catastrophic batch losses.

  5. Sep 8

    Beyond Manufacturing: Why Portal Fatigue and Physician Adoption Are Blocking Cell Therapy Access

    Is manufacturing complexity really the main bottleneck holding back cell and gene therapies, or are we ignoring the operational friction occurring right at the physician's desk? In this episode of Out of the Lab, host Nicholas Crudele sits down with Carl Schoellhammer, Partner at DeciBio, to discuss why the cell therapy industry must shift its focus from cleanroom COGS to physician awareness, simplified prescribing workflows, and clinical adoption. Carl shares his perspective on the barriers stalling patient access, comparing centralized US logistics with Europe’s decentralized hospital exemption framework and explaining why the key to scaling cell therapies lies in streamlining the entire prescribing journey. Key Takeaways: The Manufacturing Fallacy: Why COGS and production complexity are no longer the primary bottlenecks limiting cell therapy scale. Portal Fatigue: How fragmented drug scheduling systems force doctors to hunt for passwords on Post-it notes just to write a script. The European Exemption Model: How centers like Hospital Clínic de Barcelona are leveraging hospital exemption acts to dose over 500 patients in-house. Solving Logistics: Easing the administrative and travel burdens on non-metropolitan patients. Predictive Operations: How automated analytics and process monitoring can drastically lower batch failure rates.

  6. Sep 1

    The End of the Supply Chain Is the Patient: Shortages, Governance, and Risk with Dr. Angeliki Kotsianti

    What happens when a biopharma supply chain breaks upstream from the clinic? It doesn't just delay manufacturing, it forces doctors at the bedside to choose which patients receive curative therapy and which ones have to wait. In this episode of Out of the Lab, host Nicholas Crudele sits down with Dr. Angeliki Kotsianti, founder and scientific advisor of Oncolyze and former Senior Global Medical Benefit Risk Lead at Pfizer. Drawing on her unique perspective as both a treating physician and a senior biopharma executive, Angeliki breaks down why drug shortages must be re-framed as clinical events, how evolving regulatory guidance (like Computer Software Assurance) demands human medical judgment, and why operational governance must be engineered into drug development from day one. Key Takeaways: The Bedside Realities of Shortages: Lessons from the 2009 oncology supply chain crisis and why single-source dependencies leave zero buffer for clinical delivery. Shortage as a Clinical Event: How manufacturing line downtime, API consolidation, and quality deviations directly impact medical choices and patient survival. Human Accountability vs. Automation: Why software tools cannot take management decisions or replace clinical judgment when evaluating patient exposure. Designing the Line from the Outset: Why operationalizing advanced therapies requires one owner across the entire pathway from bench to patient.

  7. Aug 25

    Global Competition, Tech Transfer Traps, and Cost Reduction Realities with Alfred Sloan

    In this episode of Out of the Lab, host Nico sits down with 20-year cell and gene therapy expert Alfred Sloan to dissect the operational and capital constraints facing advanced therapy development today. From the pressure to rapidly accelerate clinical timelines to the rising threat of global competition outcasting domestic manufacturing costs, Alfred breaks down why the industry must shift from isolated IP retention to scalable, repeatable manufacturing frameworks. Key Discussion Points: The Scalability Gap: Why existing technologies fail to scale seamlessly from research to commercial production. Global Competition & Medical Tourism: How overseas government subsidies and collaborative models threaten to outpace US manufacturing within five years. Tech Transfer Traps: Why handing over a paper SOP to a CDMO leads to $100,000 run failures and how continuous technical support bridges the gap. Operational Cost Reduction: Navigating master service agreements, expediting fees, modular "widget" approaches, and standardizing assembly-line manufacturing. Timestamps: 00:01:25 – Capital Constraints and Clinical Acceleration 00:03:27 – The Scalability Bottleneck Across Development Stages 00:06:28 – Breaking Down Knowledge Sharing and IP Barriers 00:11:36 – Global Competition, Government Subsidies, and Medical Tourism 00:16:43 – Operational Cost Reduction: Vendor Lock-In, Expediting Fees, and Modular Systems 00:20:50 – Tech Transfer Realities: The Limits of Paper SOPs and Scaling Microliters to Liters 00:26:26 – Asset Acquisition vs. Building from Scratch 00:33:27 – Supply Chain Vulnerabilities, Reagent Shortages, and Modular Platforms

  8. Aug 18

    Designing for Resilience: Why CGT Supply Chain Begins Years Before Tech Transfer | Mehran Bhatti

    How do 1 in 16 cell and gene therapies fail, not because of the biology, but because of the supply chain? In this episode of Out of the Lab, host Nico sits down with Mehran, a seasoned Cell & Gene Therapy supply chain consultant, to dissect why operational resilience must be engineered into your product long before tech transfer ever takes place. From CDMO selection gaps to un-addressable spend and non-standard Bill of Materials (BOM) choices, Mehran exposes the hidden operational traps that trigger FDA Complete Response Letters (CRLs) and derail launches. In this episode, we cover: Who Owns Resilience? Why supply chain expertise must intersect with early CMC and process development. The CDMO Bottleneck: Unpacking why 40% of manufacturing-related FDA hurdles stem from partner selection and process optimization gaps. Addressable vs. Non-Addressable Spend: Why 42% of materials get locked in filings and how to optimize raw material selection up front. Real-World Harmonization: Lessons from J&J’s Carvykti pipeline on managing apheresis variability and standardizing network supply. The Future of Orchestration: How AI and predictive analytics are transforming patient slotting, scheduling, and apheresis quality. Timestamps & Chapters: 00:00 – Introduction: Supply chain resilience in Cell & Gene Therapy 02:03 – Who owns resilience? Bridging CMC, process development, and supply chain 04:57 – CDMO partner selection & commercial readiness 06:21 – The cost of failure: CRLs, manufacturing quality, and CDMO gaps 08:05 – Process ownership vs. CDMO lock-in: Lessons from J&J and apheresis 12:21 – Addressable vs. non-addressable spend in biomanufacturing 16:38 – The 50 mL Syringe Example: Why process engineers need supply chain optics 20:15 – Geopolitical risk, tariffs, and global facility harmonization 24:18 – Built-in network resilience: Lessons from radiopharmaceuticals 28:20 – Logistics, cold-chain, and patient orchestration in Europe vs. US 34:34 – The role of data, AI, and predictive analytics in apheresis quality

See All (46)

About

In Cell & Gene Therapy, opportunity created by openly discussing operational reality far outweighs the micro-risk of looking unpolished. By building a safe, unscripted space where experts can talk naturally about real work, we stop pretending everything is fine and start building the solutions needed to actually fix the system. Explore our Solution: https://www.methodmade.ca/?utm_source=podcast&utm_medium=show_notes&utm_campaign=out_of_the_lab

Information

You Might Also Like